How to Analyze a Healthcare Company

What it takes to analyze a healthcare company

To analyze a healthcare company, and especially a drugmaker, start from a feature no other major industry shares: its best products carry a built-in expiration date. A patent grants years of exclusive sales during which a successful medicine can earn enormous margins, and then the patent expires, generic copies flood in, and the price collapses. No other major industry has quite this pattern of guaranteed high profits followed by a guaranteed cliff. Analyzing one means always looking at two things at once: what it earns today, and what happens when today's patents run out.

That duality reshapes the usual questions. A high current margin is not automatically a sign of durability, because it may rest on a drug about to lose protection. The durable value sits in the research engine, the ability to keep inventing new products to replace the ones that go off patent. So the analysis leans heavily on the pipeline and on whether research spending actually produces winners.

Johnson & Johnson is a useful anchor because its scale and diversification soften the cliff. In fiscal 2025 it earned revenue of about $94.2 billion and net income near $26.8 billion, with a gross margin around 72.8 percent and research spending of roughly $14.7 billion, about 15.6 percent of revenue, according to its 10-K. Eli Lilly makes an instructive contrast: in fiscal 2025 it spent about $13.3 billion on research, a heavier 20.5 percent of its $65.2 billion in revenue, per its 10-K, reflecting a more concentrated bet on a smaller set of fast-growing drugs. The metrics below let you weigh models like these.

The pipeline against the patent cliff

The central tension in drug-company analysis is the pipeline versus the patent cliff, because the pipeline is what must replace the revenue the cliff takes away. Every blockbuster drug is on a countdown to losing exclusivity, and when it does, a medicine earning billions a year can shed most of that within a year or two as generics or biosimilars undercut it. The question is never just how good the current drugs are, but whether the next ones are ready.

Assessing the pipeline means looking at what is in development and how far along it is. Candidates in late-stage trials are closer to approval and carry less uncertainty than early-stage ones, so a pipeline weighted toward late stages is more reassuring. It also matters whether the pipeline targets large markets that could produce the next major seller, rather than a scattering of small ones. A company facing a wave of patent expirations with a thin, early-stage pipeline is in a far weaker position than one with several promising drugs near the finish line. The honest way to weigh this is to look a few years out and ask which of today's biggest sellers lose protection over that window, then whether the drugs advancing through late-stage trials are large enough to fill the hole they leave behind.

This is where diversification changes the risk. A broad company like Johnson & Johnson, spread across pharmaceuticals and medical technology, feels any single patent loss less sharply, because no one product dominates. A more concentrated company enjoys faster growth when its key drugs succeed but faces a steeper drop if a flagship product stumbles or its patent lapses without a ready replacement. Neither is better in the abstract; the point is to know which you are holding. The general habit of asking what could go wrong is developed in understanding business risks.

R&D productivity: is the research paying off?

Research and development productivity asks the decisive question about a drugmaker: does its research spending actually turn into approved, profitable products? R&D is the largest discretionary cost in the business and the source of all future revenue, so a company that spends heavily but produces few winners is quietly destroying value, while one that converts research into a steady stream of approvals is compounding it.

There is no single clean ratio for this, which is why it takes judgment. The useful signals include a consistent flow of new drug approvals over the years, new products that reach large markets and become meaningful sellers, and a pipeline that keeps refilling as older candidates graduate. You are looking for evidence that the research engine works, not just that it is expensive. Eli Lilly's recent surge, with revenue rising from about $45.0 billion in fiscal 2024 to $65.2 billion in fiscal 2025 on the strength of its newer drugs, per its 10-K, is what productive R&D looks like when it pays off; the heavy 20.5 percent of revenue it reinvests is the fuel.

The trap is to reward spending for its own sake. High R&D as a share of revenue is necessary in this industry, but it is a cost, not an achievement, until it produces approvals. A company whose research budget keeps climbing while approvals stall is showing a failing engine, however impressive the spending looks. Acquisitions muddy this further, because a drugmaker that cannot invent enough internally can buy pipelines instead, which may be sound capital allocation or may be an expensive way to paper over a weak research engine. The revealing question is whether the company is generating its own winners or repeatedly paying up for other people's, and at what price. Because so much of a drugmaker's worth rests on research that has not yet borne fruit, the free cash flow it generates today should be read alongside the reinvestment it demands, using the lens in what is free cash flow?.

Payer concentration and regulatory risk

The buyer of healthcare is usually not the patient, and that fact drives two of the sector's biggest risks. Payer concentration describes how much of a company's revenue depends on a small number of payers, typically governments and large insurers, who negotiate prices and decide what they will cover. Because these payers hold real bargaining power, a treatment's revenue depends not only on whether it works, but on whether the payers agree to pay for it and at what price.

High dependence on a single payer or government program adds risk, because a change in that payer's rules, a lower reimbursement, a coverage restriction, a new negotiation, can hit revenue hard and suddenly, without warning and outside the company's control. A company selling to many payers across many countries is more insulated than one leaning on one program, because no single decision can undo it. This is a form of the customer-concentration risk that weakens any business, examined in identifying competitive advantages (moats), where diversified demand is part of what makes a moat durable.

Regulatory risk is the harder cousin, and the honest way to frame it is as uncertainty to weigh, not an event to predict. Drug approvals, pricing legislation, and patent challenges are genuinely unpredictable, and an investor who claims to know how a trial or a ruling will turn out is guessing. The disciplined response is not to forecast the outcome but to prefer companies diversified enough to survive a bad one, and to demand a larger margin of safety in the price to compensate for the range of things that could go wrong. Pretending the uncertainty away is the real mistake.

What good looks like

A durable healthcare company shows a pipeline that can replace expiring revenue, a research engine with a track record of producing approvals, revenue spread across enough payers and geographies to absorb a setback, and a balance sheet strong enough to fund research through lean patches. The table below contrasts the resilient and the exposed, with illustrative benchmark figures rather than any single company.

The overarching discipline is to resist the temptation to bet on a single drug or a single ruling. Healthcare offers some of the most durable franchises in the market, protected by patents, know-how, and regulatory barriers, but it also offers some of the sharpest cliffs. Favoring breadth and a research engine that demonstrably works, rather than a lottery ticket on one candidate, is what separates investing in the sector from speculating in it, a distinction that runs through how to identify high-quality businesses.

Where to go from here

Analyzing a healthcare company means holding two questions together: what it earns now, and whether its pipeline and research engine can replace what the patent cliff will take. Judge R&D by the approvals it produces, understand who really pays, and treat regulatory outcomes as risks to price rather than events to call. From here, compare a different intangible moat in how to analyze a consumer brand, and a business where research becomes recurring revenue instead of a patent cliff in how to analyze a software company. To study a real name, open the Johnson & Johnson financials on Tenet.